bioRxivNeurosciencePreprint
The molecular mechanism of uptake and cell-to-cell transmission of arginine-containing dipeptide repeat proteins.
Alexandra B. SutteriD, Benito F. Buksh, Jelena Mojsilovic‐PetroviciD, Casey DaltoniD, Nicholas A. TilliD, Danielle C. MorganiD, David W. C. MacMillaniD, Robert Gordon KalbiD
Abstract
Micro-satellite repeat expansion of the 5 GGGGCC 3 sequence in the C9orf72 gene is the most common monogenic form of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). Dipeptide repeat proteins (DPRs) translated from the mutant allele can be detected in postmortem brains of afflicted individuals. The arginine containing peptides, poly-PR and poly-GR, are particularly noxious to cells. Both have been shown to undergo cell-cell transmission, but the underlying mechanisms are not understood. We found rapid internalization and nucleolar localization of bath-applied hemagglutinin (HA) tagged poly-PR with twenty repeats (HA-PR20) in cell lines and neurons. Small molecule and RNAi approaches implicated a temperature-dependent, fluid phase endocytosis mechanism in HA-PR20 uptake. We sought to identify DPR-related cell surface uptake factors using a high-resolution proximity labeling technique developed in the MacMillan group, termed {micro}Map. DPR-iridium conjugates identified candidate cell-surface proteins which were interrogated in an RNAi screen. Focusing on our strongest candidate, chondroitin sulfate proteoglycan 4 (CSPG4), we showed that cellular uptake of HA-PR20 is blocked by inhibition of glycosaminoglycan chain synthesis (using drugs or RNAi) and knockdown or ablation of CSPG4 (using RNAi or CRISPR editing). Reduction of CSPG4 protected PR20-induced neuronal toxicity. We used a dual reporter system to interrogate in vitro neuron-to-neuron transmission of PR50 and found that PR50 synthesized by one neuron readily spread to neighboring neurons. Transmission was significantly reduced when CSPG4 was knocked down. These results suggest CSPG4 is an important factor in poly-PR internalization and transmission and therefore may be a therapeutic target to slow DPR transmission and disease progression. Significance StatementA GGGGCC hexanucleotide repeat expansion in the C9orf72 gene is the most common monogenic form of ALS/FTD. This expansion leads to dipeptide repeat protein (DPR) production through non-canonical translation of repeat-containing RNA. DPRs have been shown to transmit between cells, but how this occurs is not well understood. We identified the cell surface protein chondroitin sulfate proteoglycan 4 (CSPG4) as a mediator of the uptake and intercellular spread of toxic arginine-rich DPRs. Targeting CSPG4 may provide a strategy to block DPR transmission and slow disease progression.
- organism: human
- assay: proteomics
- research focus: cell type annotation
- research focus: differential expression
- approach: statistical model
- approach: experimental assay
- Citations
- 0
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- C9orf72-derived poly-GA DPRs undergo endocytic uptake in iNPC-derived astrocytes and spread to motor neurons
Paolo M. Marchi, Lara Marrone, … Mimoun Azzouz·bioRxiv·Oct 11, 2021
- Inhibiting toxicity of ALS-linked dipeptide repeat proteins by polystyrene sulfonate (PSS)
Anna Bratek‐Skicki, Junaid Ahmed, … Péter Tompa·bioRxiv·May 19, 2023
- C9orf72 arginine-rich dipeptide repeat proteins disrupt importin β-mediated nuclear import
L. R. Hayes, L. Duan, … J. D. Rothstein·bioRxiv·Sep 30, 2019
- C9ORF72 dipeptide repeat proteins disrupt formation of GEM bodies and induce aberrant accumulation of survival of motor neuron protein
Yuma Kato, Minnie Yokogawa, … Hitomi Tsuiji·bioRxiv·Mar 24, 2021
- C9orf72-derived arginine-containing dipeptide repeats associate with axonal transport machinery and impede microtubule-based motility
Laura Fumagalli, Florence L. Young, … Philip Van Damme·Science AdvancesPeer-reviewed·Apr 9, 2021
- Type I PRMT inhibition protects against C9ORF72 arginine-rich dipeptide repeat toxicity
Alan S. Premasiri, Anna L. Gill, Fernando G. Vieira·Frontiers in PharmacologyPeer-reviewed·Sep 8, 2020